Javascript is not enabled.

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.

Skip to content
Content starts here
CLOSE ×
Search
Leaving AARP.org Website

You are now leaving AARP.org and going to a website that is not operated by AARP. A different privacy policy and terms of service will apply.

FDA Authorizes Emergency Use of Remdesivir to Treat COVID-19

Preliminary results find drug helps hospitalized coronavirus patients recover faster

08 April 2020, Hamburg: An ampoule of the drug Remdesivir is on the table during a press conference at the University Hospital Eppendorf (UKE). The hospital management informed about the start of the study with the Ebola drug Remdesivir in particularly severely ill patients with Covid-19. Photo by: Ulrich Perrey/picture-alliance/dpa/AP Images
A vial of the drug remdesivir is on a table during a press conference.
Ulrich Perrey/picture-alliance/dpa/AP Images

The Food and Drug Administration (FDA) on Friday issued an emergency use authorization for Gilead Sciences’ antiviral drug remdesivir as a treatment option for people who are hospitalized with COVID-19, the illness caused by the new coronavirus. To date, the virus has killed more than 237,000 people worldwide.

The news comes just days after the National Institutes of Health announced preliminary results from an international clinical trial testing remdesivir as a potential treatment for COVID-19. Researchers found that patients with severe illness who received the drug recovered faster than those who received a placebo. “Results also suggested a survival benefit,” the NIH said in a news release. The mortality rate for the group that received remdesivir was lower than for the placebo group.

member card

AARP Membership — $12 for your first year when you sign up for Automatic Renewal

Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine.

Join Now

The emergency use authorization — which is not the same as official FDA approval — “allows for remdesivir to be distributed in the U.S. and administered intravenously by health care providers” to treat patients who have low blood oxygen levels or who need breathing support by way of a mechanical ventilator.

"Based on evaluation of the emergency use authorization criteria and the scientific evidence available, it was determined that it is reasonable to believe that remdesivir may be effective in treating COVID-19, and that, given there are no adequate, approved, or available alternative treatments, the known and potential benefits to treat this serious or life-threatening virus currently outweigh the known and potential risks of the drug's use,” the FDA said in a news release.

During public health emergencies, the FDA has the power to bypass its normally lengthy approval process to allow “unapproved medical products or unapproved uses of approved medical products” to diagnose, treat or prevent serious or life-threatening diseases or conditions “when there are no adequate, approved, and available alternatives.”

There is no approved treatment for COVID-19 and no vaccine for the coronavirus, which emerged in December and has since sickened millions worldwide. In March, the FDA authorized the emergency use of two malaria drugs, chloroquine and hydroxychloroquine, to treat COVID-19. Less than a month later, on April 24, the FDA warned doctors over use of the two antimalarials, citing serious and potentially life-threatening heart rhythm problems.

In Friday's announcement, FDA Commissioner Stephen Hahn said, “Today's action is an important step in our efforts to collaborate with innovators and researchers to provide sick patients timely access to new therapies where appropriate, while at the same time supporting research to further evaluate whether they are safe and effective.”

membership-card-w-shadow-192x134

AARP Membership — $12 for your first year when you sign up for Automatic Renewal

Get instant access to members-only products and hundreds of discounts, a free second membership, and a subscription to AARP the Magazine.